News Praxis soars on rare childhood epilepsy trial data Praxis looks like it could be filing for approval of two products next year, after its childhood epilepsy drug delivered a win in a pivotal trial.
News Case builds for Biogen, Stoke's Dravet syndrome drug Hopes have risen for a new treatment for severe childhood epilepsy Dravet syndrome, on the back of new data for Biogen and Stoke's zorevunersen.
Views & Analysis Taking on the challenge of childhood epilepsy Japan’s Eisai has a long-term commitment to treating epilepsy, with a series of therapies already on the market - but with many different forms of the disease, requiring different therapeutic appro
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.